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A B S T R A C T
Homocysteine (Hcy) is a sulfur-containing amino acid involved in methionine metabolism. An elevated
total plasma Hcy concentration (tHcy) is a risk factor for vascular disease. The present study aimed to
assess the role of antiepileptic drugs (AEDs) and C677T methylenetetrahydrofolate (MTHFR)
polymorphisms on tHcy in pediatric patients with epilepsy treated for at least 6 months with various
treatment regimens protocols including the newer AEDs.
The study group was recruited from children and adolescents with epilepsy followed up in the Child
Neuropsychiatry Clinic of the Second University of Naples, between January 2007 and March 2008.
Inclusion criteria were: (1) patients with epilepsy, treated with one or more anticonvulsant drugs for at
least 6 months; (2) age between 2 and 16 years. Plasma tHcy concentrations were considered elevated
when they exceeded 10.4 mmol/L, and folate concentrations <3 ng/mL were considered deﬁcient. Serum
vitamin B12 levels were considered normal between 230 and 1200 pg/mL. The study group was
composed of 78 patients (35 males, 43 females), aged between 3 and 15 years (mean 8.9 years). Thirty-
ﬁve patients were taking AED monotherapy, 43 polytherapy. Sixty-three healthy sex- and age-matched
children and adolescents served as controls. The mean tHcy value in the patient group was higher than
the mean value in the control group (12.11  7.68 mmol/L vs 7.4  4.01 mmol/L; p < 0.01).
DNA analysis for the MTHFR C677T polymorphism showed the CT genotype in 46%, CC in 35% and TT
in 17.8% of cases. Decreased folic acid serum levels signiﬁcantly correlated with increased tHcy levels
(p < 0.003). Female sex was a less signiﬁcant risk factor for increased tHcy levels (p = 0.039).
Our study conﬁrms the association between hyperhomocysteinemia and epilepsy. The elevation of
tHcy is essentially related to low folate levels. Correction of poor folate status, through supplementation,
remains the most effective approach to normalize tHcy levels in patients on AED mono- or polytherapy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
In the last decade, a relationship between increased total
homocysteine plasma (tHcy) levels and antiepileptic treatments,
has been recognized.1–9
The folate level may be one of the determinants of serum tHcy,
in particular in older children treated with more than one
antiepileptic drugs (AEDs).1,4,6,10* Corresponding author at: Child and Adolescent Neuropsychiatry, Medical
School, University of Salerno, S. Giovanni di Dio e Ruggi d’Aragona Hospital, Largo
d’Ippocrate, 84100 Salerno, Italy. Tel.: +39 089 672507; fax: +39 089 672507;
mobile: +39 3382747593.
E-mail address: gcoppola@unisa.it (G. Coppola).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2012.02.011The duration of therapy has also been recognized as a potential
risk factor.6 The are conﬂicting11 results about the role of
methylenetetrahydrofolate reductase (MTHFR) polymorphisms
(particularly the C677T and A1298C) as determinants of high
tHcy levels in this patient group. MTHFR is a key enzyme in the
production of 5-methyltetrahydrofolate, which is required as the
methyl donor for Hcy remethylation to methionine. The C677T
mutation of the MTHFR gene decreases the activity of this enzyme.
High homocysteine blood levels for age have been found to have
potential NMDA-mediated proconvulsant effects and are acknowl-
edged as a vascular risk factor linked to toxic effects on the arterial
endothelium.12 Previous studies have demonstrated the effect of
anticonvulsant monotherapy on tHyc levels in adult patients.6–12
It was the aim of the present study to assess the effects
of monotherapy versus polytherapy and the role of MTHFRvier Ltd. All rights reserved.
G. Coppola et al. / Seizure 21 (2012) 340–343 341polymorphism on tHcy levels in a pediatric population affected by
epilepsy treated with older and new generation AEDs.
2. Methods
The patients reported in this study were identiﬁed prospec-
tively at the Department of Child Neuropsychiatry of the Second
University of Naples and were enrolled between January 2007 and
March 2008.
Inclusion criteria were: (1) patients with epilepsy, treated with
one or more than one AEDs for at least 6 months; (2) age from 2
years old. Exclusion criteria included: neurometabolic or systemic
diseases, chronic therapy with other than antiepileptic drugs and
current or previous treatment with folic acid and/or other
vitamins.
Sixty-three healthy controls who had no clinical and/or
laboratory evidence of metabolic and/or endocrine diseases were
studied. Controls were recruited from outpatients of the Depart-
ment of Child Neuropsychiatry of the Second University of Naples:
these subjects had been referred for non-epileptic problems e.g.
episodic headache, minor head trauma, and dizziness.
2.1. Vitamin preparations were not prescribed to any subjects
Informed consent was obtained by parents and controls and,
when possible, by patients. The study was approved by the Ethical
Committee of the Faculty of Medicine, Second University of Naples,
Italy.
All patients and controls underwent the following examina-
tions: haematochemistry and liver/kidney function evaluation,
blood and urine amino acids and urine organic acids assessment,
dosage of serum levels of folic acid, vitamin B12, tHcy and
anticonvulsant drugs. DNA was extracted from peripheral blood
by using a previously published method14 of genotypization
(MTHFR) and was available from all subjects who agreed to
participate.
Venous blood samples were collected in the morning, after an
overnight fast. Blood samples were immediately processed in
order to prevent artefactual variations of tHcy, due to the products
of in vitro erythrocyte metabolism.13 Plasma and serum aliquots
were quickly separated and frozen at 80 8C for batch analysis.
tHcy levels were determined via ﬂuorescence polarization
immunoassay (AXYM ABBOT Laboratories).14
Serum vitamin B12, and serum folate concentrations were
determined using commercial kits (ACS Ciba-Corning, and
Immulite, DPC).
In each patient, isolation of DNA was performed by using
Wizard Genomic DNA Puriﬁcation kit according to the manufac-
turer. The MTHFR C677T mutation was detected via polymerase
chain reaction (PCR) ampliﬁcation of genomic DNA, followed by
restriction fragment length polymorphism (RFLP) analysis.15
Genotypization was accomplished examining the occurrence
of a HinfI recognition site. Brieﬂy, PCR 198 bp product was
obtained via ampliﬁcation using a mastercycler gradient thermal
cycler (eppendorf). The primer pair used was: sense 50-
CGAAGCAGGGAGCTTTGAGG-30, reverse 50-AGGACGGTGCGG-
TGAGAGTG-30. PCR product was digested with HinfI endonucle-
ase, yielding a mayor 175 bp fragment in the presence of
the C677T mutation. Bands were resolved on 3% agarose gel
electrophoresis. All determinations were repeated twice in two
separate runs.
Plasma tHcy concentrations were considered elevated when
they exceeded 10.4 mmol/L, according with Huemer et al.16 Folate
concentrations <3 ng/mL were considered deﬁcient, as reported by
Ono et al.17 Serum vitamin B12 levels were considered in normal
range between 230 and 1200 pg/mL.2.2. Statistical analysis
Student’s t-test for unpaired data was used to compare tHcy
concentrations of patients and controls.
Fisher’s exact test was performed for relation of univariate
analysis and multiple logistic regression analysis was used to
analyze factors of inﬂuence on high and low tHcy concentrations,
odds ratio and conﬁdence interval were calculated for each
variable. SPSS version17 was used for statistical analysis (SPSS,
Chicago).
p < 0.05 values were considered signiﬁcant.
3. Results
Seventy-eight (35 male, 43 female) children and adolescents,
ranging in age from 3.1 to 15.0 (mean + SD, 8.9 + 6.4) years were
included in the study. The patients suffered from the following
types of epilepsy: generalized epilepsy, 40 (cryptogenic, 23);
partial epilepsy, 18 (cryptogenic, 10); refractory epileptic enceph-
alopathies, 20 (Dravet syndrome, 3; Lennox-Gastaut syndrome, 4;
lissencephaly, 2; brain atrophy, 11).
Thirty-ﬁve patients were treated with monotherapy (Valproic
Acid (VPA), 20; Carbamazepine (CBZ), 10; Levetiracetam (LEV), 5),
and 43 patients with polytherapy. Mean duration of drug
treatment was of 4.8 years (range 1–10 years). Forty-six patients
(58.9%) were seizure-free.
Patients’ mean tHcy value was signiﬁcantly higher than that of
controls (11.31  6.68 mmol/L vs 7.4  4.01 mmol/L; p < 0.01).
Overall, 32 patients (41.0%) showed tHcy 10.4 mmol/L (mean
15.11  4.68; median 13.97). Out of 32 patients with hyperhomocys-
teinemia, 10 were treated with monotherapy (VPA, 6; CBZ, 3; LEV, 1)
and 22 with polytherapy (12 on 2 AEDs and 10 on three drugs) (Table 1).
Three out of 10 patients (30%) on monotherapy and 8 out of 22 (36.4%)
on polytherapy were taking enzyme-inducing anticonvulsant drugs.
The most frequent drug combinations were: VPA + Lamotrigine (LTG)
(6), CBZ + Topiramate (TPM) (4), VPA + LTG + Clobazam (2) and
VPA + LTG + TPM (2). Table 2 shows the most frequently used AEDs.
Our patients showed the following distribution of MTHFR
polymorphism: CT (46%), CC (35%), and TT (17.8%). Folic acid
concentration was <3 ng/mL in 33 patients (range 1.3–2.9, mean
1.9); 19 out of 33 patients (59.4%) showed increased tHcy levels.
Vitamin B12 was increased in 17 patients (21.8%) (range 1270–
1980 pg/mL, mean 1621) and 7 of these had abnormal tHcy levels
(Table 1). Multiple logistic regression data analysis showed a
signiﬁcant negative correlation between folic acid serum levels
and tHcy levels (p < 0.003); to a lesser extent, female sex proved to
be a signiﬁcant risk factor for high tHcy levels (p = 0.039) (Table 3).
4. Discussion
In the present study, pediatric patients with epilepsy treated
with old and/or newer AEDs showed tHcy plasma levels higher
than control subjects. More speciﬁcally about 40% of children and
adolescents had hyperhomocysteinemia. These data are in
agreement with previous reports,9,18,19 showing tHcy increase in
10–30% patients taking AEDs.
It is noteworthy that most previous reports described patients
treated with VPA, CBZ or Phenobarbital monotherapy in chil-
dren1,3–5,20 or adults.6,21 In our series, there was no signiﬁcant
relationship between C677T polymorphism and plasma tHcy
levels. In this respect, data emerging from literature are still
controversial. Indeed, while some authors found that the MTHFR
polymorphisms C677T, A1298C and G1793A play no role in
determining abnormal levels of plasma tHcy in patients treated
with CBZ or VPA monotherapy11,16,20 or combination therapy,11
other authors8,19,23,24 reported that patients with epilepsy and the
Table 1
Comparison between patients with tHcy blood level < or > 10.4 mmol/L.
Pts. with homocysteine 10.4 mmol/L (tot. 32)* Pts. with homocysteine 10.4 mmol/L (tot. 46)o p
Homocysteine blood value (mean  SD) (median) 15.11  4.68 (13.97) 6.71  2.44 (7.01)
Duration of therapy (mean-SD) (median) 5  2.59 (5) 4.67  2.89 (4.0) NS
Monotherapy (n. pts) 10* 25o
Politherapy (n. pts) 22* 21o
MTHFR polymorphisms
C677T 16 20
T677T 9 5
C677C 7 21
Age (mean  SD) (median) 9.71  4.08 (10.5) 8.56  4.30 (7.5) NS
Sex (M/F) 12/20 23/23 NS
B12 vitamin (>800 ng/mL) 7 10 0.218
Folic acid (<3 ng/mL) 19 14 0.001
* p = 0.006 (at Fisher’s exact test).
o p = 0.381 (at Fisher’s exact test).
Table 2
Most frequently used anticonvulsant drugs in our series (tot. 78 pts).
Anticonvulsant drug No. of patients %
Valproic acid 43 55.1
Carbamazepine 24 30.7
Lamotrigine 16 20.5
Topiramate 14 17.9
Levetiracetam 7 8.9
Zonisamide 7 8.9
Clobazam 7 8.9
Phenobarbital 5 6.4
Clonazepam 4 5.1
Ethosuccimide 1 1.3
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treated with CBZ or PHT. In addition, C677T/A1298C polymor-
phisms of MTHFR were signiﬁcantly more frequent in epilepsy
patients treated with enzyme-inducing drugs and lower plasma
level of folic acid. Therefore, Caccamo et al.,19 state that the TT677/
AA1298 diplotype is mostly closely linked to developing hyper-
homocysteinemia, while CC677/AA1298 may play a protective
role, being present more frequently in controls.
Furthermore, Sniezawska et al.24 reported polymorphisms of
MTHFD1GG (G1958A) related to increased tHcy levels in epileptic
patients.
In keeping with other studies, treatment duration had not clear
effect on tHcy values in our data.11,20 In contrast, Sener et al.6 found
a signiﬁcant relationship between therapy duration and folic acid
levels, thus excluding any link with tHcy levels. Furthermore, no
relationship was found between plasma levels of AEDSs and serum
tHcy.1,5
Polytherapy (2 AEDs) has been reported as being associated
with higher levels of tHcy by Huemer et al.16 and Tu¨mer et al.3
while in another study,11 multidrug therapy was signiﬁcantlyTable 3
Multiple logistic regression (odds ratio and conﬁdence interval were calculated for
each variable).
Model term Odds ratio 95% CI p-Value
Lower Upper
% Const 0.55 0.15 1.94 0.350
Age 1.38 0.35 5.40 0.645
Folate 4.89 1.70 14.05 0.003
B12 vitamin 0.87 0.21 3.57 0.852
MTHFR genotype 1.36 0.69 2.70 0.376
Therapy 1.18 0.36 3.87 0.788
VPA 0.65 0.22 1.90 0.428
Therapy duration 1.05 0.29 3.79 0.945
Sex 0.26 0.07 0.93 0.039correlated with higher tHcy serum levels, especially in patients
who were TT homozygous for the C677T mutation and less in the
CT heterozygous or CC wild type patients. Conversely, in our
sample, there was no signiﬁcant correlation between mono/
polytherapy and tHcy levels.
In the literature, CBZ and VPA have been associated with higher
tHcy levels and lower serum folate levels than those found in
controls.1,4,5,20 These differences were more pronounced in
patients treated with CBZ.5 In addition, the enzyme inducing
AEDs (CBZ, PHT, PB) were associated with higher levels of tHcy
compared with VPA.2,22
In almost all studies, old generation AEDs have predominantly
been used monotherapy; only few patients were taking more
recently introduced AEDs, like TPM, LTG and oxcarbazepine.16
In relation to folate levels, several studies have found a
signiﬁcant inverse association between low levels of folate and
higher tHcy levels in patients with epilepsy, taking either mono- or
polytherapy.1,2,4–6,8,11,16,20
Folate supplementation induced tHcy normalization in all
patients.8,21 A key role for circulating folate levels is also conﬁrmed
in our study; in fact, folic acid was the only factor signiﬁcantly
related to serum tHcy levels by multiple logistic regression
analysis. Accordingly, the relationship between the C677T muta-
tion and increased tHcy was strongly inﬂuenced by folate status. In
fact, the large majority of homozygous individuals with low
plasma folate had increased tHcy, while those with high plasma
folate levels showed normal tHcy levels.25
Our study has at least three limitations: ﬁrst of all, the number
of patients on different drugs is too small to come to ﬁrm
conclusions about the effects of individual drugs; moreover, our
group of patients is inhomogeneous because almost all patients
were taking new AEDs in combination with old AEDs; ﬁnally, this is
a cross-sectional (rather than prospective longitudinal) study.
Therefore, no ﬁnal conclusion can then be drawn about low folate
levels as a possible risk factors for high tHcy levels. Further
investigations are needed to verify our data.
In conclusion, our experience conﬁrms that hyperhomocystei-
nemia is common in children receiving antiepileptic drug
treatment for epilepsy. This increase is mainly related to low
folate levels, which are the main determinant for tHcy normaliza-
tion in patients on antiepileptic therapy.
Considering the vascular risk associated with high tHcy the
assessment of blood levels of tHcy and folate is warranted in the
routine evaluation of treated epileptic patients and folate
substitution should be considered.
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